Details for New Drug Application (NDA): 210434
✉ Email this page to a colleague
NDA 210434 describes ALBENDAZOLE, which is a drug marketed by Actavis Elizabeth, Alembic, Chartwell Rx, Cipla Ltd, Dr Reddys, Edenbridge Pharms, MSN, Strides Pharma, and Zydus Pharms, and is included in nine NDAs. It is available from fifteen suppliers. Additional details are available on the ALBENDAZOLE profile page.
The generic ingredient in ALBENDAZOLE is albendazole. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the albendazole profile page.
The generic ingredient in ALBENDAZOLE is albendazole. There are ten drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the albendazole profile page.
Summary for 210434
| Tradename: | ALBENDAZOLE |
| Applicant: | Cipla Ltd |
| Ingredient: | albendazole |
| Patents: | 0 |
Pharmacology for NDA: 210434
| Mechanism of Action | Cytochrome P450 1A Inducers |
Medical Subject Heading (MeSH) Categories for 210434
Suppliers and Packaging for NDA: 210434
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ALBENDAZOLE | albendazole | TABLET;ORAL | 210434 | ANDA | Cipla USA Inc. | 69097-237 | 69097-237-72 | 2 TABLET in 1 BOTTLE (69097-237-72) |
| ALBENDAZOLE | albendazole | TABLET;ORAL | 210434 | ANDA | Cipla USA Inc. | 69097-237 | 69097-237-73 | 28 TABLET in 1 BOTTLE (69097-237-73) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Sep 21, 2018 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
